Prenoxad: first opioid antidote for non-clinician use

Martindale has launched Prenoxad (naloxone), the first licensed opioid overdose treatment for use by non-healthcare professionals in the community setting.

Prenoxad is administered intramuscularly into the outer thigh or upper arm and is intended for emergency use in the home or other non-medical setting.
Prenoxad is administered intramuscularly into the outer thigh or upper arm and is intended for emergency use in the home or other non-medical setting.

Supplied in a kit containing a pre-filled syringe and two needles, Prenoxad (naloxone) is licensed for emergency use to reverse life-threatening respiratory depression caused by natural or synthetic opioids. It should be administered by intramuscular injection as part of a resuscitation intervention.

Prenoxad is intended to be carried by individuals at risk of opioid overdose. Prescribers must assess the competence of the patient or representative to administer the product in the appropriate circumstances.

View Prenoxad drug record

Further information: Martindale

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more